Sa1631 Weight Change, Non-Alcoholic Fatty Liver Disease and Metabolic Complications Post-Liver Transplantation

2016 ◽  
Vol 150 (4) ◽  
pp. S1081
Author(s):  
Xiao Ying Li ◽  
Yuhanis Sunny ◽  
Hiang Keat Tan ◽  
Yet Hua Loh
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Fatty Liver ◽  
Weight Change ◽  
Fatty Liver Disease ◽  
Metabolic Complications ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation

2022 ◽  
Vol 8 ◽  
Author(s):  
Speranta Iacob ◽  
Susanne Beckebaum ◽  
Razvan Iacob ◽  
Cristian Gheorghe ◽  
Vito Cicinnati ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Fatty Liver ◽  
Life Style ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Recurrent Nash ◽  
Alcoholic Fatty Liver Disease

Recurrent or de novo non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) following liver transplantation (LT) is a frequent event being increasingly recognized over the last decade, but the influence of recurrent NASH on graft and patient outcomes is not yet established. Taking into consideration the long term survival of liver transplanted patients and long term complications with associated morbidity and mortality, it is important to define and minimize risk factors for recurrent NAFLD/NASH. Metabolic syndrome, obesity, dyslipidemia, diabetes mellitus are life style risk factors that can be potentially modified by various interventions and thus, decrease the risk of recurrent NAFLD/NASH. On the other hand, genetic factors like recipient and/or donor PNPLA3, TM6SF2, GCKR, MBOAT7 or ADIPOQ gene polymorphisms proved to be risk factors for recurrent NASH. Personalized interventions to influence the different metabolic disorders occurring after LT in order to minimize the risks, as well as genetic screening of donors and recipients should be performed pre-LT in order to achieve diagnosis and treatment as early as possible.

scholarly journals Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease

2019 ◽  
Vol 20 (9) ◽  
pp. 2215 ◽  
Author(s):  
Hamza El Hadi ◽  
Angelo Di Vincenzo ◽  
Roberto Vettor ◽  
Marco Rossato
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Disorders ◽  
Current Understanding ◽  
Metabolic Complications ◽  
Alcoholic Fatty Liver ◽  
Increased Risk ◽  
Stroke Type ◽  
Alcoholic Fatty Liver Disease

With the progressive epidemics of obesity, non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in adults and children. The increasing prevalence and incidence of NAFLD with advanced fibrosis is concerning because patients appear to experience higher non-liver-related morbidity and mortality than the general population. Recent clinical evidence suggests that NAFLD is directly associated with an increased risk of cardio-metabolic disorders. This mini review describes briefly the current understanding of the pathogenesis of NAFLD, summarizing the link between NAFLD and cardio-metabolic complications, focusing mainly upon ischemic stroke, type 2 diabetes mellitus (DM), hypertension, chronic kidney disease (CKD) and cardiac arrhythmias. In addition, it describes briefly the current understanding of the pathogenesis of NAFLD.

scholarly journals Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0224820 ◽  
Author(s):  
Denisa Erhartova ◽  
Monika Cahova ◽  
Helena Dankova ◽  
Marie Heczkova ◽  
Irena Mikova ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy

2019 ◽  
Vol 91 (2) ◽  
pp. 109-117 ◽  
Author(s):  
M V Maevskaya ◽  
V T Ivashkin ◽  
K V Ivashkin ◽  
V D Lunkov ◽  
E O Liusina ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Complex Treatment ◽  
Metabolic Complications ◽  
Alcoholic Fatty Liver ◽  
Cardiometabolic Diseases ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

The article presents an update of the role of non-alcoholic fatty liver disease (NAFLD) in cardiometabolic diseases and events: arterial hypertension and components of the metabolic syndrome. A review of NAFLD modern pharmacotherapy has been conducted. Particular attention is paid to the place of ursodeoxycholic acid in the complex treatment of NAFLD.

Sign in / Sign up

Export Citation Format

Share Document